United Neuroscience to Present Alzheimer's Vaccine Clinical Trial Update at CTAD 2018

DUBLIN, Oct. 18, 2018 /PRNewswire/ -- United Neuroscience (UNS), a clinical-stage biotech company pioneering a new class of medicine to treat and prevent brain disorders, today announced that the company will present a clinical trial update for its lead vaccine candidate, UB-311, at the International Conference on Clinical Trials for Alzheimer's Disease (CTAD), which takes place Oct. 24-27 in Barcelona. CTAD's goal is to bring together leaders in the treatment of Alzheimer's disease to discuss new results, candidate therapeutics and procedural issues to help develop the next generation of Alzheimer's disease treatments.

"We are highly encouraged by the progress of our Alzheimer's vaccine program and remain on track to announce top-line data from our Phase IIa study before the end of the year," said Mei Mei Hu, Chief Executive Officer of United Neuroscience. "Alzheimer's disease is one of the greatest challenges in the world of medicine, and United Neuroscience is committed to developing innovative technologies for this growing patient population."

Ajay Verma, M.D., Ph.D., the company's Chief Medical Officer, added, "We are eager to examine the anti-Aβ antibody response elicited by the different boosting schedules in our Phase IIa study. The multiple brain MRI and amyloid PET scans included in our study will help us to objectively assess safety and target engagement." 

Oral Presentation Details:

Active Anti-amyloid Immunotherapy with UB-311 Vaccine: Design, baseline data and study update of a Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel-Group, Multicenter Study

Presenter: Ajay Verma, M.D., Ph.D., CMO of United Neuroscience
Date: Oct. 25, 2018
Time: 9:15 a.m. – 9:30 a.m. CEST
Location: Palau de Catalunya Conference Center
Presentation Number: OC4

About UB-311 in Alzheimer's Disease

Active vaccination of human individuals against Aβ has yet to be safely and effectively achieved. Other active vaccine efforts have either reported low antibody titers and responder rates or significant safety issues such as T-cell mediated encephalitis. The most advanced Alzheimer's vaccine in all clinical development, UB-311 is currently in a Phase IIa study with top-line results expected by the end of the year. In the Phase I study, UB-311 vaccination safely elevated anti-Aβ antibodies in all patients with a suggestion of cognitive stabilization. UB-311 is a novel UBITh™ active vaccine targeting the N-terminus of Aβ that is designed to induce high B-cell specific responses while avoiding T-cell inflammation. UB-311 was shown to generate site-specific antibodies across mice, guinea pigs, macaques and baboons and to reduce Aβ1–42 oligomers, protofibrils and plaque load in a transgenic mouse model of Alzheimer's disease.

About United Neuroscience

United Neuroscience (UNS) is a clinical-stage biotech company dedicated to the development of best-in-class immunotherapeutics for the brain. A global company headquartered in Dublin, Ireland, with operations in Taiwan and the United States, UNS was founded to address the social and economic burden of Alzheimer's and other neurodegenerative diseases and seeks to rapidly advance candidates into and through clinical trials with the goal of delivering breakthrough treatments to patients. For more information please visit www.unitedneuroscience.com.

Follow UNS on Twitter at https://twitter.com/UNSTechBio and on LinkedIn at https://www.linkedin.com/company/unitedneuroscience.

Media Contacts

David Schull or Brittanie Dougherty
Russo Partners, LLC
(212) 845-4271
(646) 942-5634
[email protected]
[email protected]

SOURCE United Neuroscience

Related Links

http://www.unitedneuroscience.com